MMP-9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK). by Zaman, K. et al.
The Swiss Oncology Research Network
SAKK Coordinating Center
Effingerstrasse 40, CH-3008 Bern 
sakkcc@sakk.ch
http://sakk.ch
Acknowledgments:
Swiss Federation against Cancer (Oncosuisse), the Swiss State Secretariat for Education and Research (SER) and Roche Switzerland for their support.
MMP-9 as predictive factor for response and progression free survival in breast cancer patients 
treated with bevacizumab and pegylated liposomal doxorubicin.
A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
K. Zaman1, C. Rochlitz2, T. Ruhstaller3, B. Thürlimann3, S. Aebi4, R. von Moos5, Ch. Mamot6, N. Gabriel7, L. Rossier-Pansier1, R. Stupp1, S. Crowe8, C. Ruegg1
1CePO, University Hospital, Lausanne; 2University Hospital Basel; 3Kantonsspital St. Gallen; 4Medical Oncology, University Hospital Bern; 5Kantonsspital Chur; 6Kantonsspital Aarau; 7University Hospital Zürich,8Statistics Unit, SAKK Coordination Center, Bern, Switzerland.
Number: P2-16-07
Poster presented at the 33rd Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, Texas; December 2010
The benefit of bevacizumab (Bv) has been shown in different tumors including
colorectal cancer, renal cancer, pulmonary non-small cell cancer and also
breast cancer. However to date, there is no established test evaluating the
angiogenic status of a patient and monitoring the effects of anti-angiogenic
treatments.
Tumor angiogenesis is the result of a balance between multiple pro- and anti-
angiogenic molecules. There is very little published clinical data exploring the
impact of the anti-angiogenic therapy on the different angiogenesis-related
molecules and the potential role of these molecules as prognostic or
predictive factors.
We measured prospectively the levels of 6 angiogenesis-related molecules in
the peripheral blood of breast cancer patients treated with a combination of Bv
and pegylated liposomal doxorubicin (PLD):
 VEGF: Vascular endothelial growth factor is a potent pro-angiogenic factor. VEGF 
was shown to be related to breast cancer stage, prognosis and possibly response to 
treatment. 
 VEGFR-2 (KDR/Flk-1): VEGF-receptor-2 is the main receptor inducing VEGF-
response. sVEGFR-2 = soluble VEGFR-2.
 VEGFR-1 (Flt-1): VEGF-receptor-1 is considered to be an endogenous negative 
regulator of angiogenesis by binding and inactivating circulating VEGF. However its 
function is poorly understood. sVEGFR-1 = soluble VEGFR-1.
 VEGFR-3 (Flt-4): VEGF-receptor-3 is involved in lymphangiogenesis, but is also 
expressed on endothelial cells of angiogenic blood vessels. sVEGFR-3= soluble 
VEGFR-3.
 MMP-9: Matrix metalloproteinase 9 plays a critical role in tissue remodeling during 
development in pathological processes. Functional interdependence was described 
between VEGF and MMP-92. 
 PlGF: Placenta growth factor promotes migration of endothelial cells for neo-
angiogenesis and metastasis. PlGF is a ligand of VEGFR-1.
Objective
The objective of this substudy is to identify surrogate markers of angiogenesis
in advanced breast cancer patients treated with the combination of PLD and
Bv.
Main eligibility criteria for patients included in the SAKK 24/06 trial:
 Cytologically or histologically proven breast cancer, either metastatic or locally
recurrent inoperable and HER2-negative
 Measurable disease according to RECIST
 Normal heart function (LVEF  55%) and WHO performance status 0 or 1
 No previous chemotherapy for metastatic or inoperable locally recurrent breast
cancer; no previous adjuvant or neo-adjuvant chemotherapy within 12 months before
registration
Blood sampling:
- 20 ml of blood were taken: 10 ml for serum and 10 ml for plasma (EDTA-K)
- The samples were processed rapidly and frozen at -80 C
(transient conservation at -20 C was allowed)
Time points:
1. Baseline (before first trial treatment administration)
2. After 2 cycles of treatment (2 months)
3. Every 3 months until progression or trial treatment interruption
4. At treatment discontinuation
Measurement of the angiogenesis-related molecules:
- Enzyme-linked immunosorbent assays (Quantikine, R&D Systems and Reliatech)
were used to measure the molecules
- The measurements were done centrally in our laboratory (CePO and ISREC,
Epalinges, Switzerland).
Statistical considerations:
For the measure of circulating angiogenesis-related factors, all analyses were
descriptive and exploratory. Hence, p-values were not corrected for multiple testing
and thus considered statistically significant for p  0.05.
The log-transformed data (to reduce the skewness) for each marker was analyzed
using an analysis of variance (ANOVA) model to determine if there was a difference
between the mean of the subgroups of interest, (CR+PR vs PD, CR+PR+SD vs PD)
where = 0.05. The untransformed data was also analyzed in the same manner as a
sensitivity check.
Box-plots of the log-transformed data of the main molecules categorized into the
subgroups of interest were produced. Cox proportional hazards regression models
were also investigated using the baseline levels as a covariate for each molecule.
Results
 A total number of 43 patients were included in the SAKK 24/06 trial.
 41 patients participated in this translational substudy across 11 Swiss centers.
 A total of 132 samples were collected.
Relationship between baseline levels and treatment effect
An ANOVA was used to determine if there was a difference in the means between the
subgroups of interest.
Conclusions
Relationship between baseline levels and outcome
Figure 3: Baseline plasma level of MMP-9 vs PFS
Our exploratory results suggest that:
1- The baseline plasma level of MMP-9 was associated with tumor 
response and disease control to PLD-Bv.
2- The baseline plasma level of MMP-9 could predict PFS.
3- The baseline plasma level of sVEGFR-1 was associated with 
disease control.
Therefore, these results justify further assessment of MMP-9 and 
sVEGFR-1 as predictive or prognostic factors in breast cancer patients 
treated with anti-angiogenic therapies. 
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Treatment schedule 
Combination therapy q 4 weeks:
¾ PLD 20 mg/m2 i.v.
Day 1 and 15 (max. of 6 cycles)
¾ Bevacizumab 10 mg/kg i.v.
Days 1 and 15
Monotherapy q 4 weeks:
¾ Bevacizumab 10 mg/kg i.v.
Days 1 and 15
PD
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Figure 1: Box-plot of log-transformed plasma level of MMP-9 for best response
Figure 2: Box-plot of log-transformed plasma level of sVEGFR-1 for best response
There were no statistically significant differences in the log-transformed levels of the other
angiogenesis-related molecules (VEGF, VEGFR-2, VEGFR-3 or PlGF) between the
subgroups of interest.
Subgroup Log-fold 
change
(1) 
CR+PR vs PD 0.8786
(2) 
CR+PR+SD vs PD 0.8427
Responding = CR or PR,  disease control =  CR + PR + stable disease, progression = progression as defined by 
RECIST criteria v1.0
Subgroup Log-fold 
change
(1) 
CR+PR vs PD -0.8160 
(2) 
CR+PR+SD vs PD -1.0289 
p-value=0.0008
p-value=0.0540
p=0.0202
p=0.0035
Figure 4: Survival function estimates vs PFS
The log-transformed level of 
MMP-9 at baseline was 
identified as a significant 
prognostic factor using a Cox 
proportional hazards model in 
terms of PFS: p=0.0417, 
hazard ratio (HR)=0.574 with 
a corresponding 95% 
confidence interval 
(0.336 - 0.979).
The survivor function 
estimates were obtained for 
the log-transformed level of 
MMP-9 at baseline grouped 
into low (>= median) and 
high (> median). These two 
groups were compared 
using a log-rank test: 
p=0.0408.
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